2025
Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer
Sundaresan V, Leapman M. Debate 1: Radical Prostatectomy For the Right Patient With High-Risk Prostate Cancer. Seminars In Radiation Oncology 2025, 35: 385-392. PMID: 40516973, DOI: 10.1016/j.semradonc.2025.05.001.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyRadical prostatectomyProstate cancerDeprivation therapyHigh riskEffect of long-term androgen-deprivation therapyLong-term androgen deprivation therapyAdequate randomized clinical trialsLong-term cancer controlHigh-risk prostate cancerRisk of gastrointestinal toxicityDisease-related survivalProportion of patientsDegrees of metastatic potentialResponse to treatmentRandomized clinical trialsCourse of treatmentSequence of surgeryLocal salvageRadiation therapySecondary malignanciesGastrointestinal toxicityInitial surgeryMultimodal treatmentHealth-related quality of lifeAssociation between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden.
Palencia P, Zhao X, Kandala K, Smani S, Sivanesan N, Cavallo J, Leapman M. Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17123.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate radiation therapyMetastatic prostate cancerOverall survivalRadiation therapyProstate cancerM1c diseaseTreatment modalitiesRT to ADTTreated with androgen deprivation therapyAssociated with improved overall survivalHormone-sensitive prostate cancerAssociated with poor overall survivalPrimary local therapyExternal beam radiotherapyGleason grade groupCompare overall survivalNational Cancer DatabaseProstate cancer metastasisLog-rank testDisease burdenKaplan-Meier curvesCox proportional hazards modelsLow disease burdenARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
Armstrong A, Petrylak D, Shore N, Szmulewitz R, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad A. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). Journal Of Clinical Oncology 2025, 43: 5005-5005. DOI: 10.1200/jco.2025.43.16_suppl.5005.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyOverall survivalOS analysisRadiographic progression-free survivalHormone-sensitive prostate cancerLong-term follow-upGlobal phase 3Low-volume patientsOpen-label enzalutamideProgression-free survivalEfficacy of enzalutamideMedian Follow-UpOpen-label extensionKaplan-Meier methodLong-term efficacyStandard-of-careClinically relevant subgroupsCox regression modelsFollow-up dataARCH trialDocetaxel useMedian OSAndrogen deprivationDisease volumeAndrogen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
Pinski J, Ingles S, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17109.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerProgression free survivalResponse to androgen deprivation therapyAndrogen metabolism genesAndrogen deprivation therapyPrimary prostate tumorsProstate cancerPSA responsePSA-CRDeprivation therapyProstate tumorsMolecular features of prostate cancerCastration-sensitive prostate cancerAnalysis of progression free survivalFeatures of prostate cancerResponse to hormonal therapyDays of follow-upAndrogen receptor inhibitorsTumor gene expression profilesUnder-expressedExpression levelsFree survivalAssociation of expression levelsHormone therapyTumor blocksTRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
Ong M, Sokolova A, Hotte S, Dorff T, Chi K, Wyatt A, Goldkorn A, Kolinsky M, Brundage M, Ndika A, Lerner S, Parulekar W, Ding K, Jafri M. TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps5129.Peer-Reviewed Original ResearchMetastatic castration sensitive prostate cancerAndrogen receptor pathway inhibitorsAndrogen deprivation therapyPSA responseOverall survivalDisease volumePredictive value of circulating tumor DNADocetaxel to androgen deprivation therapyReceipt of androgen deprivation therapyResponse to androgen deprivation therapyMonths of androgen deprivation therapyAndrogen deprivation therapy initiationCastration sensitive prostate cancerClinical progression free survivalMonths median overall survivalStandard androgen deprivation therapyECOG performance status 0Pathway inhibitorRandomized phase III trialPresence of liver metastasesAbsence of randomized dataRandomized phase III clinical trialsPrimary prostate cancer tissuesNational Clinical Trials NetworkPhase III clinical trialsProstate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis
Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman M, Kramer G, Hussain M, Merseburger A, Briganti A, D'Amico A, Gillessen S, Saad F, Shariat S. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus 2025 PMID: 40379533, DOI: 10.1016/j.euf.2025.03.019.Peer-Reviewed Original ResearchAndrogen receptor pathway inhibitorsPSA responseProstate-specific antigen reductionAssociated with better OSProstate-specific antigenAndrogen deprivation therapyCastration-resistant PCOverall survivalProstate cancerTreated with androgen deprivation therapyHazard ratioMetastatic castration-resistant PCMetastatic hormone-sensitive PCNonmetastatic castration-resistant PCProstate-specific antigen responsePathway inhibitorBaseline PSA measurementHormone-sensitive PCUndetectable PSA levelsAdvanced prostate cancerAssociated with OSRandom-effects meta-analysesDeprivation therapyPSA levelsPSA measurementsEnzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer
Azad A, Petrylak D, Iguchi T, Shore N, Villers A, Gomez-Veiga F, Alcaraz A, Alekseev B, Szmulewitz R, Holzbeierlein J, Rosbrook B, Ma J, Zohren F, El-Chaar N, Haas G, Stenzl A, Armstrong A. Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer. JAMA Network Open 2025, 8: e258751. PMID: 40332939, PMCID: PMC12059972, DOI: 10.1001/jamanetworkopen.2025.8751.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerProstate-specific antigen levelRadiographic progression-free survivalUndetectable prostate-specific antigenAndrogen deprivation therapyProstate-specific antigenProstate-specific antigen declineClinical outcomesOverall survivalProstate cancerClinical trialsHazard ratioPatients treated with enzalutamideHormone-sensitive prostate cancerPhase 3 randomized clinical trialAssociated with improved survivalStudy enrollmentProgression-free survivalMetastatic prostate cancerRadiographic disease progressionClinical end pointsPost hoc secondary analysisRandomized clinical trialsReduced riskSecondary analysisAdvances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer
Smani S, DuBois J, Ajjawi I, Sohoni N, Choksi A, Lokeshwar S, Kim I, Renzulli J. Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer. Journal Of Clinical Medicine 2025, 14: 2565. PMID: 40283395, PMCID: PMC12028174, DOI: 10.3390/jcm14082565.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyAndrogen receptor signaling inhibitorsHormone-sensitive prostate cancerCombination therapyProstate cancerHigh-volume metastatic diseaseProgression to castration resistancePSMA PET-CTLow-volume diseaseOverall survival benefitCurrent treatment paradigmDetection of metastasesBalance treatment efficacyPersonalized treatment strategiesOptimal treatment selectionStandard of careCytoreductive prostatectomyDoublet therapyPrecision-based approachesTriplet therapyCastration resistanceDeprivation therapyMetastatic diseaseRadiation therapyPembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhöfer T, Gurney H, Kramer G, Bergman A, Zalewski P, De Santis M, Armstrong A, Gerritsen W, Pachynski R, Byun S, Retz M, Levesque E, McDermott R, Bracarda S, Manneh R, Levartovsky M, Li X, Schloss C, Poehlein C, Fizazi K. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. Journal Of Clinical Oncology 2025, 43: 1638-1649. PMID: 40043230, PMCID: PMC12058370, DOI: 10.1200/jco-24-01283.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTreat metastatic castration-resistant prostate cancerRadiographic progression-free survivalAndrogen receptor pathway inhibitorsCastration-resistant prostate cancerTreatment-related adverse eventsStandard of careAdverse eventsOverall survivalDouble-blindProstate cancerMedian radiographic progression-free survivalDual primary end pointsImmune-mediated adverse eventsEnd pointsBlinded independent central reviewData cutoff dateSafety of pembrolizumabAndrogen deprivation therapyProgression-free survivalIndependent central reviewSecondary end pointsPrimary end pointConcomitant prednisoneMedian OSAssociation of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition.
Sowalsky A, Wilkinson S, Ku A, Lis R, King I, Low D, Trostel S, Baj A, Kartal S, Heyward K, Vo B, Jansen C, Ye H, Harmon S, Kissick H, Pinto P, Choyke P, Turkbey B, Dahut W, Karzai F. Association of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition. Journal Of Clinical Oncology 2025, 43: 401-401. DOI: 10.1200/jco.2025.43.5_suppl.401.Peer-Reviewed Original ResearchAndrogen deprivation therapyPathological responseHER2 activationRadical prostatectomyAR activityProstate tumorsHER2 inhibitionProstate cancerMultiplex immunofluorescenceAndrogen receptorMonths prior to radical prostatectomyLocalized high-risk prostate cancerHigh-risk prostate cancerInitiation of neoadjuvant therapyNeoadjuvant androgen deprivation therapyHER2 inhibitorsFlow cytometryTreated with low dosesAssociated with poor outcomesHigh-risk PCIntensive hormone therapyOccult micrometastatic diseasePoor pathologic responseResidual cancer volumeHuman prostate tumorsTime to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
Sayegh N, Jo Y, Swami U, Hage Chehade C, Ozay Z, Gebrael G, Maughan B, Plets M, Hussain M, Dorff T, Lara P, Goldkorn A, Lerner S, Agarwal N. Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial. Journal Of Clinical Oncology 2025, 43: 173-173. DOI: 10.1200/jco.2025.43.5_suppl.173.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalOverall survivalMetachronous diseaseMetastatic hormone-sensitive prostate cancerInitial prostate cancer diagnosisTiming of metastatic diseaseHormone-sensitive prostate cancerSubgroups of ptsTime of prostatectomyTime to metastasisCox proportional hazards modelsProstate cancer diagnosisProportional hazards modelDeprivation therapyGleason scoreMetastatic diseaseMetastatic recurrenceMetastatic diagnosisPrognostic factorsPerformance statusProstate cancerPrognostic valueSurvival outcomesProstatectomyEvaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial.
Sokolova A, Tangen C, Hussain M, Sweeney C, Dorff T, Thompson I, Lerner S. Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. Journal Of Clinical Oncology 2025, 43: 268-268. DOI: 10.1200/jco.2025.43.5_suppl.268.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerPSA responseAndrogen deprivation therapyProstate-specific antigenContinuous androgen deprivation therapyContinuous ADTOverall survivalDisease extentCox regressionHormone-sensitive prostate cancerAssociated with worse OSDe-intensification strategiesBaseline clinical featuresSubsets of patientsTreatment effectsDeprivation therapyImproved OSExtensive diseaseMinimal diseasePrognostic significanceProstate cancerOptimal therapyCox analysisLymph nodesPrognostic marker
2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara P, Thompson I, Hussain M, Dorff T, Lerner S, Agarwal N. Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. European Urology Oncology 2024, 8: 612-615. PMID: 39521639, PMCID: PMC12059143, DOI: 10.1016/j.euo.2024.10.013.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerAndrogen deprivation therapyBody mass indexAssociated with better OSHigher Body Mass IndexOverall survivalPhase 3 trialProstate cancerMass indexMetastatic castration-resistant prostate cancerAssociated with better overall survivalBaseline prostate-specific antigenCastration-resistant prostate cancerNormal body mass indexIncidence of visceral metastasesBaseline body mass indexZubrod performance statusCorrelation of body mass indexAnalysis of patient-level dataProstate-specific antigenGroup of patientsPost hoc exploratory analysisRisk of deathMedian OSOutcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo P, Zanardi E, Rossetti S, Davidsohn M, Eid M, Zarif T, McClure H, Spinelli G, Damassi A, Murianni V, Vauchier C, Oliveira T, Malgeri A, Modesti M, Mestre R, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E, Group S. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study. Clinical Genitourinary Cancer 2024, 22: 102185. PMID: 39217072, DOI: 10.1016/j.clgc.2024.102185.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetate plus prednisoneAndrogen deprivation therapyCancer-specific survivalCastration-sensitive prostate cancerFirst-line therapyProstate cancerAdverse eventsFailure of androgen deprivation therapyMedian cancer-specific survivalCastration-resistant prostate cancerAcetate plus prednisoneInternational multicenter registryMedian Follow-UpKaplan-Meier methodFirst-line treatmentUpfront docetaxelDeprivation therapyAbiraterone acetatePrimary endpointSurvival outcomesMulticenter registryADT+DFollow-upBone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer
Gebrael G, Jo Y, Swami U, Plets M, Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2419966. PMID: 38980676, PMCID: PMC11234233, DOI: 10.1001/jamanetworkopen.2024.19966.Peer-Reviewed Original ResearchConceptsProgression-free survivalAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerBone painOverall survivalPost hoc secondary analysisProstate cancerSurvival outcomesPain statusAssociated with shorter progression-free survivalClinical trialsPresence of bone painProstate-specific antigen levelAssociated with worse overall survivalCastration-resistant prostate cancerShorter progression-free survivalIntention-to-treat populationSecondary analysisZubrod performance statusHigh-volume diseaseCompare survival outcomesCox proportional hazards regression modelsSecondary end pointsProportional hazards regression modelsARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
Petrylak D, McKean M, Lang J, Gao X, Dreicer R, Geynisman D, Stewart T, Gandhi M, Appleman L, Dorff T, Chatta G, Tutrone R, De La Cerda J, Berghorn E, Gong J, Yu T, Dominy E, Chan E, Shore N. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. Journal Of Clinical Oncology 2024, 42: 5011-5011. DOI: 10.1200/jco.2024.42.16_suppl.5011.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTreatment-related adverse eventsAR-LBD mutationsPhase 1/2 studyClinical activityProstate cancerAndrogen receptorAdverse eventsMetastatic castration-resistant prostate cancer treatmentProgressive metastatic castration-resistant prostate cancerPhase 1 dose-escalation portionDisease progressionTreatment-emergent adverse eventsCastration-resistant prostate cancerResistant to available therapiesAssociated with poor outcomesDose-limiting toxicityAndrogen deprivation therapyAdvanced prostate cancerIncreased blood creatinineWild-type ARSubgroup of patientsDose-dependent increaseDeprivation therapyPretreated patientsThree- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Parikh M, Tangen C, Hussain M, Gupta S, Callis S, Jo Y, Harzstark A, Paller C, George S, Zibelman M, Cheng H, Maughan B, Zhang J, Pachynski R, Bryce A, Lin D, Quinn D, Lerner S, Thompson I, Dorff T, Lara P, Agarwal N. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. European Urology Oncology 2024, 7: 1097-1104. PMID: 38523017, PMCID: PMC12037053, DOI: 10.1016/j.euo.2024.03.001.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerProstate-specific antigenAndrogen deprivation therapyProstate-specific antigen levelOverall survivalProstate cancerDeprivation therapyComplete responseAntigen levelsNo responseTreatment of metastatic hormone-sensitive prostate cancerLow prostate-specific antigen levelsResponse to androgen deprivation therapyAssociated with improved OSPSA responsePhase 3 randomized trialPhase 3 clinical trialsEarly identification of patientsAssociated with OSHigher risk of deathIdentification of patientsResponse to treatmentRisk of deathOS associationLigand‐gated ion channels as potential biomarkers for ADT‐mediated cognitive decline in prostate cancer patients
Verma S, Singh V, Nagampalli V, Ponsky L, Li C, Chao H, Gupta S. Ligand‐gated ion channels as potential biomarkers for ADT‐mediated cognitive decline in prostate cancer patients. Molecular Carcinogenesis 2024, 63: 1051-1063. PMID: 38482990, PMCID: PMC11096008, DOI: 10.1002/mc.23708.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyN-methyl-D-aspartate receptorsGamma-aminobutyric acidLigand-gated ion channelsType 1 angiotensin II receptorGlial cellsAndrogen signaling inhibitorsProstate cancer cell culture modelHigher risk of cognitive dysfunctionProstate cancer patientsPotential biomarkersBrain-derived neurotrophic factorCognitive dysfunctionIon channelsProtein-protein interaction network analysisAngiotensin II receptorsNuclear receptor subfamily 3 group C member 1Real-time polymerase chain reaction assayBrain glial cellsCytokine-cytokine receptor interactionCancer cell culture modelsAnalysis of genesGene-disease associationsInteraction network analysisPolymerase chain reaction assayBaseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial. Journal Of Clinical Oncology 2024, 42: 188-188. DOI: 10.1200/jco.2024.42.4_suppl.188.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerProgression-free survivalAndrogen deprivation therapyBone painOverall survivalGleason scoreProstate cancerPrognostic markerAssociated with decreased PFSDisease burdenMedian progression-free survivalHormone-sensitive prostate cancerCastration-resistant prostate cancerCox proportional hazards modelsConfidence intervalsPatient-level analysisProportional hazards modelDeprivation therapyHigher disease burdenBone metastasesPain statusSurvival outcomesPatient-level dataTreatment intensificationPrognostic variablesIntensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Posadas E, Gay H, Rodgers J, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Boike T, Jurgens D, Wong A, Shen X, Miyawaki L, Bland C, Hairston J, Sandler H, Pugh S, Feng F. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2024, 42: 131-131. DOI: 10.1200/jco.2024.42.4_suppl.131.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression free survivalSalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsRadical prostatectomyLHRH analogsDecreased lymphocytesAndrogen receptorMonths of androgen deprivation therapyGrade 3 adverse eventsProgression free survival benefitStandard androgen deprivation therapyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyProstate cancer patientsEnzalutamide armGleason 9Salvage radiationDeprivation therapyNodal involvementFree survivalRT boost
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply